Orexigen Insists Revised Contrave Data Should Not Affect Timing Of NDA

FDA tells the biotech corrections to secondary endpoint data for one pivotal study for its diet pill filing comprise only a clinical amendment.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet